Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 1 of 13 PageID #: 2692
`Case 1:24-cv-00053-TSK Document17-6 Filed 06/12/24 Page 1of13 PagelD #: 2692
`
`EXHIBIT 4
`EXHIBIT 4
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 2 of 13 PageID #: 2693
`
`From:
`To:
`Cc:
`
`Subject:
`Date:
`
`Brett A. Postal
`Kayali, Kathryn; Aviv Zalcenstein; Robert Oakes; Laura Fairneny; Neil B. McLaughlin; Terri Mascherin
`Patel, Priyata; Mike Cottler; Shaun Van Horn; John R. Labbe; Argall, Arthur; M710 Team; Jamie.Obrien@steptoe-
`johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept; WFG-aflibercept@willkie.com;
`mhissam@hfdrlaw.com; Carl Shaffer; Andrew Robey; Max Gottlieb; QE - Samsung Bioepis;
`skl@schraderlaw.com; clt@simmermanlaw.com; fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE -
`Formycon Team; MGB-Amgen-ABP938; ABP938; REGENERONPATENT@lists.kellogghansen.com;
`drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell; Kaitlyn McKitrick;
`Eylea.Biosimilars@weil.com; Eylea
`RE: In re aflibercept - May 10 submission m/c
`Thursday, June 6, 2024 8:04:57 PM
`
`Kat:
`Thank you for confirming that Regeneron will be producing to Amgen any and all documents you
`received from the other Defendants on June 5. We interpret your commitment to produce them “on
`or about Tuesday, June 11, 2024" to mean, at most, one calendar day beyond June 11. We request
`that you expedite this production to the extent possible, given that you will already be producing
`these materials after the start of Amgen’s response period.
`
`Finally, we continue to disagree with your suggestion that Regeneron’s proposed changes to the
`protective orders are necessary. Throughout this case, Amgen has been open to discussing
`reasonable and appropriate ways to facilitate access to redacted versions of documents, including
`sealed court filings. As you know, Amgen proposed a stipulation to that end on June 4, which
`incorporated revisions endorsed by Formycon, SB, Celltrion, and Biocon.
`We note that Formycon, Samsung, and Celltrion have stated they are available to meet and confer
`on Monday, June 10th, from 10am-12pm. Amgen can also be available between 11:30am and noon
`ET on Monday June 10th.
`Best,
`Brett
`
`
`
`Brett A. Postal
`901 New York Avenue, NW
`Suite 900 East
`Washington, D.C. 20001
`
`Main Number: 202.783.6040
`Fax Number: 202.783.6031
`Email: bpostal@rothwellfigg.com
`Website: www.rothwellfigg.com
`
`The information contained in this electronic message and any attachments to this message are intended for the exclusive use of the
`addressee(s) and may contain confidential and/or privileged information. If you are not the addressee, note that any disclosure, copy,
`distribution or use of the contents of this message is prohibited. If you are not the intended recipient, please notify Rothwell, Figg, Ernst &
`Manbeck, P.C. immediately at (202) 783-6040 or email us at bpostal@rfem.com, and destroy all copies of this message and any
`attachments.
`
`-----Original Message-----
`From: Kayali, Kathryn <KKayali@wc.com>
`Sent: Thursday, June 6, 2024 4:33 PM
`To: Brett A. Postal <bpostal@rothwellfigg.com>; Aviv Zalcenstein <azalcenstein@geminilaw.com>;
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 3 of 13 PageID #: 2694
`
`Robert Oakes <RMO@FR.com>; Laura Fairneny <laurafairneny@quinnemanuel.com>; Neil B.
`McLaughlin <NMcLaughlin@rmmslegal.com>; Terri Mascherin <tmascherin@jenner.com>
`Cc: Patel, Priyata <Priyata.Patel@weil.com>; Mike Cottler <mcottler@geminilaw.com>; Shaun Van
`Horn <vanhorn@fr.com>; John R. Labbe <jlabbe@marshallip.com>; Argall, Arthur
`<aargall@wc.com>; M710 Team <M710Team@rmmslegal.com>; Jamie.Obrien@steptoe-
`johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept <DG-
`Aflibercept@NETORG8512690.onmicrosoft.com>; WFG-aflibercept@willkie.com;
`mhissam@hfdrlaw.com; Carl Shaffer <cshaffer@hfdrlaw.com>; Andrew Robey
`<arobey@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com>; skl@schraderlaw.com; clt@simmermanlaw.com;
`fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE - Formycon Team <SERVICE-
`Formycon_Team@fr.com>; MGB-Amgen-ABP938 <MGB-Amgen-ABP938@marshallip.com>; ABP938
`<ABP938@rothwellfigg.com>; REGENERONPATENT@lists.kellogghansen.com;
`drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell
`<ahardestyodell@bowlesrice.com>; Kaitlyn McKitrick <kmckitrick@bowlesrice.com>;
`Eylea.Biosimilars@weil.com; Eylea <Eylea@wc.com>
`Subject: RE: In re aflibercept - May 10 submission m/c
`
`Brett:
`
`Again, we disagree with your characterizations. Our request that Defendants promptly agree to our
`proposed changes to the applicable protective orders were intended to accommodate Amgen’s
`demand that Defendants produce to Amgen documents containing Regeneron’s confidential
`information on June 5th. We maintain that those amendments are necessary to avoid further, ad-
`hoc productions of this nature, and also to ensure that Regeneron has the same ability to utilize
`information produced across cases as Defendants do. Please provide availability to meet and confer
`on Monday, June 12 concerning those amendments.
`
`Regardless, we are in receipt of Defendants’ redacted documents. We are loading them into our
`discovery system, will code them for confidentiality (a given document may require different
`confidentiality designations for Amgen than for other Defendants), stamp them with Bates Nos., and
`produce them promptly to all Defendants. We therefore anticipate being able to produce them on
`or about Tuesday, June 11, 2024.
`
`Furthermore, we received the necessary permissions from IQVIA late last night. This authorization
`will allow us to avoid further redactions to these new documents and will permit us to produce
`additional financial information to Amgen. Because the financial documents have already been
`produced to other Defendants and therefore have already been processed for production, we
`expect to provide them on Friday.
`
`Best,
`
`Kat
`
`Kathryn S. Kayali
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 4 of 13 PageID #: 2695
`
`Williams & Connolly LLP
`680 Maine Avenue S.W., Washington, DC 20024
`(P) 202-434-5644 | (F) 202-434-5029
`kkayali@wc.com<mailto:kkayali@wc.com> | www.wc.com<http://www.wc.com/>
`
`
`
`From: Brett A. Postal <bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>>
`Date: Thursday, Jun 06, 2024 at 10:59 AM
`To: Kayali, Kathryn <KKayali@wc.com<mailto:KKayali@wc.com>>, Aviv Zalcenstein
`<azalcenstein@geminilaw.com<mailto:azalcenstein@geminilaw.com>>, Robert Oakes
`<RMO@FR.com<mailto:RMO@FR.com>>, Laura Fairneny
`<laurafairneny@quinnemanuel.com<mailto:laurafairneny@quinnemanuel.com>>, Neil B.
`McLaughlin <NMcLaughlin@rmmslegal.com<mailto:NMcLaughlin@rmmslegal.com>>, Terri
`Mascherin <tmascherin@jenner.com<mailto:tmascherin@jenner.com>>
`Cc: Patel, Priyata <Priyata.Patel@weil.com<mailto:Priyata.Patel@weil.com>>, Mike Cottler
`<mcottler@geminilaw.com<mailto:mcottler@geminilaw.com>>, Shaun Van Horn
`<vanhorn@fr.com<mailto:vanhorn@fr.com>>, John R. Labbe
`<jlabbe@marshallip.com<mailto:jlabbe@marshallip.com>>, Argall, Arthur
`<aargall@wc.com<mailto:aargall@wc.com>>, M710 Team
`<M710Team@rmmslegal.com<mailto:M710Team@rmmslegal.com>>, Jamie.Obrien@steptoe-
`johnson.com <Jamie.Obrien@steptoe-johnson.com<mailto:Jamie.Obrien@steptoe-johnson.com>>,
`Gordon.Copland@steptoe-johnson.com <Gordon.Copland@steptoe-
`johnson.com<mailto:Gordon.Copland@steptoe-johnson.com>>, DG-Aflibercept <DG-
`Aflibercept@NETORG8512690.onmicrosoft.com<mailto:DG-
`Aflibercept@NETORG8512690.onmicrosoft.com>>, WFG-aflibercept@willkie.com <WFG-
`aflibercept@willkie.com<mailto:WFG-aflibercept@willkie.com>>, mhissam@hfdrlaw.com
`<mhissam@hfdrlaw.com<mailto:mhissam@hfdrlaw.com>>, Carl Shaffer
`<cshaffer@hfdrlaw.com<mailto:cshaffer@hfdrlaw.com>>, Andrew Robey
`<arobey@hfdrlaw.com<mailto:arobey@hfdrlaw.com>>, Max Gottlieb
`<mgottlieb@hfdrlaw.com<mailto:mgottlieb@hfdrlaw.com>>, QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com<mailto:qe-samsungbioepis@quinnemanuel.com>>,
`skl@schraderlaw.com <skl@schraderlaw.com<mailto:skl@schraderlaw.com>>,
`clt@simmermanlaw.com <clt@simmermanlaw.com<mailto:clt@simmermanlaw.com>>,
`fes@simmermanlaw.com <fes@simmermanlaw.com<mailto:fes@simmermanlaw.com>>,
`trey@simmermanlaw.com <trey@simmermanlaw.com<mailto:trey@simmermanlaw.com>>,
`SERVICE - Formycon Team <SERVICE-Formycon_Team@fr.com<mailto:SERVICE-
`Formycon_Team@fr.com>>, MGB-Amgen-ABP938 <MGB-Amgen-
`ABP938@marshallip.com<mailto:MGB-Amgen-ABP938@marshallip.com>>, ABP938
`<ABP938@rothwellfigg.com<mailto:ABP938@rothwellfigg.com>>,
`REGENERONPATENT@lists.kellogghansen.com
`<REGENERONPATENT@lists.kellogghansen.com<mailto:REGENERONPATENT@lists.kellogghansen.co
`m>>, drpogue@cdkrlaw.com <drpogue@cdkrlaw.com<mailto:drpogue@cdkrlaw.com>>,
`sruby@cdkrlaw.com <sruby@cdkrlaw.com<mailto:sruby@cdkrlaw.com>>, Ashley Hardesty Odell
`<ahardestyodell@bowlesrice.com<mailto:ahardestyodell@bowlesrice.com>>, Kaitlyn McKitrick
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 5 of 13 PageID #: 2696
`
`<kmckitrick@bowlesrice.com<mailto:kmckitrick@bowlesrice.com>>, Eylea.Biosimilars@weil.com
`<Eylea.Biosimilars@weil.com<mailto:Eylea.Biosimilars@weil.com>>, Eylea
`<Eylea@wc.com<mailto:Eylea@wc.com>>
`Subject: RE: In re aflibercept - May 10 submission m/c
`
`
`Kat,
`
`
`
`As you are aware, it took several weeks for us to settle on mutually acceptable terms for the
`stipulated protective order that is now in place. Your demand that Amgen provide a response to an
`amendment that you proposed after COB on June 4, to which presumably all defendants must agree,
`is unreasonable and unnecessary. Amgen will consider your proposal, however, that is entirely
`independent of your obligation to immediately produce to Amgen the documents that defendants
`produced to Regeneron yesterday. The email below confirms that Celltrion, Formycon, and SB have
`now served on Regeneron the categories of redacted documents that these defendants agreed to
`produce on May 30.
`
`
`
`Amgen has accommodated Regeneron’s purported need to redact IQVIA data from certain
`documents and Regeneron has not indicated that this cannot be completed within one business day.
`In fact, your 10pm June 4 email represents that Regeneron could produce the redacted documents
`while “the parties reach agreement" about amended protective orders. Due to the time sensitivity of
`these preliminary injunction proceedings, and Regeneron’s delay in raising any concern about IQVIA
`data, Amgen requires confirmation no later than 5pm ET today that you will produce these materials
`to Amgen today. If Regeneron does not so confirm, Amgen will proceed with seeking relief from the
`Court.
`
`
`
`Accordingly, please confirm no later than 5pm ET today that Regeneron will produce these
`documents to Amgen today.
`
`
`
`Best regards,
`
`Brett
`
`[cid:image001.jpg@01DAB800.9D55FD20]
`
`Brett A. Postal
`901 New York Avenue, NW
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 6 of 13 PageID #: 2697
`
`Suite 900 East
`Washington, D.C. 20001
`
`Main Number: 202.783.6040
`Fax Number: 202.783.6031
`Email: bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>
`Website: www.rothwellfigg.com<http://www.rothwellfigg.com/>
`
`The information contained in this electronic message and any attachments to this message are
`intended for the exclusive use of the addressee(s) and may contain confidential and/or privileged
`information. If you are not the addressee, note that any disclosure, copy, distribution or use of the
`contents of this message is prohibited. If you are not the intended recipient, please notify Rothwell,
`Figg, Ernst & Manbeck, P.C. immediately at (202) 783-6040 or email us at
`bpostal@rfem.com<mailto:bpostal@rfem.com>, and destroy all copies of this message and any
`attachments.
`
`
`
`-----Original Message-----
`From: Kayali, Kathryn <KKayali@wc.com>
`Sent: Wednesday, June 5, 2024 9:45 PM
`To: Aviv Zalcenstein <azalcenstein@geminilaw.com>; Brett A. Postal <bpostal@rothwellfigg.com>;
`Robert Oakes <RMO@FR.com>; Laura Fairneny <laurafairneny@quinnemanuel.com>; Neil B.
`McLaughlin <NMcLaughlin@rmmslegal.com>; Terri Mascherin <tmascherin@jenner.com>
`Cc: Patel, Priyata <Priyata.Patel@weil.com>; Mike Cottler <mcottler@geminilaw.com>; Shaun Van
`Horn <vanhorn@fr.com>; John R. Labbe <jlabbe@marshallip.com>; Argall, Arthur
`<aargall@wc.com>; M710 Team <M710Team@rmmslegal.com>; Jamie.Obrien@steptoe-
`johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept <DG-
`Aflibercept@NETORG8512690.onmicrosoft.com>; WFG-aflibercept@willkie.com;
`mhissam@hfdrlaw.com; Carl Shaffer <cshaffer@hfdrlaw.com>; Andrew Robey
`<arobey@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com>; skl@schraderlaw.com; clt@simmermanlaw.com;
`fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE - Formycon Team <SERVICE-
`Formycon_Team@fr.com>; MGB-Amgen-ABP938 <MGB-Amgen-ABP938@marshallip.com>; ABP938
`<ABP938@rothwellfigg.com>; REGENERONPATENT@lists.kellogghansen.com;
`drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell
`<ahardestyodell@bowlesrice.com>; Kaitlyn McKitrick <kmckitrick@bowlesrice.com>;
`Eylea.Biosimilars@weil.com; Eylea <Eylea@wc.com>
`Subject: RE: In re aflibercept - May 10 submission m/c
`
`
`
`Counsel:
`
`
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 7 of 13 PageID #: 2698
`
`
`We are unable to confer on Friday. Please provide times for a meet and confer on Monday, June
`10th regarding Regeneron’s proposed amendments to the protective orders.
`
`
`
`Brett: We are conferring with our client regarding Amgen’s demands in your email sent today at
`3PM, and expect to respond tomorrow. In the interim, please confirm whether Amgen objects to
`Regeneron’s proposed amendments to the stipulated protective order.
`
`
`
`Best,
`
`
`
`Kat
`
`
`
`From: Aviv Zalcenstein
`<azalcenstein@geminilaw.com<mailto:azalcenstein@geminilaw.com<mailto:azalcenstein@geminila
`w.com%3cmailto:azalcenstein@geminilaw.com>>>
`
`Date: Wednesday, Jun 05, 2024 at 8:22 PM
`
`To: Brett A. Postal
`<bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com%3
`cmailto:bpostal@rothwellfigg.com>>>, Kayali, Kathryn
`<KKayali@wc.com<mailto:KKayali@wc.com<mailto:KKayali@wc.com%3cmailto:KKayali@wc.com>>>
`, Robert Oakes
`<RMO@FR.com<mailto:RMO@FR.com<mailto:RMO@FR.com%3cmailto:RMO@FR.com>>>, Laura
`Fairneny
`<laurafairneny@quinnemanuel.com<mailto:laurafairneny@quinnemanuel.com<mailto:laurafairneny
`@quinnemanuel.com%3cmailto:laurafairneny@quinnemanuel.com>>>, Neil B. McLaughlin
`<NMcLaughlin@rmmslegal.com<mailto:NMcLaughlin@rmmslegal.com<mailto:NMcLaughlin@rmmsl
`egal.com%3cmailto:NMcLaughlin@rmmslegal.com>>>, Terri Mascherin
`<tmascherin@jenner.com<mailto:tmascherin@jenner.com<mailto:tmascherin@jenner.com%3cmail
`to:tmascherin@jenner.com>>>
`
`Cc: Patel, Priyata
`<Priyata.Patel@weil.com<mailto:Priyata.Patel@weil.com<mailto:Priyata.Patel@weil.com%3cmailto:
`Priyata.Patel@weil.com>>>, Mike Cottler
`<mcottler@geminilaw.com<mailto:mcottler@geminilaw.com<mailto:mcottler@geminilaw.com%3c
`mailto:mcottler@geminilaw.com>>>, Shaun Van Horn
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 8 of 13 PageID #: 2699
`
`<vanhorn@fr.com<mailto:vanhorn@fr.com<mailto:vanhorn@fr.com%3cmailto:vanhorn@fr.com>>>
`, John R. Labbe
`<jlabbe@marshallip.com<mailto:jlabbe@marshallip.com<mailto:jlabbe@marshallip.com%3cmailto:jl
`abbe@marshallip.com>>>, Argall, Arthur
`<aargall@wc.com<mailto:aargall@wc.com<mailto:aargall@wc.com%3cmailto:aargall@wc.com>>>,
`M710 Team
`<M710Team@rmmslegal.com<mailto:M710Team@rmmslegal.com<mailto:M710Team@rmmslegal.
`com%3cmailto:M710Team@rmmslegal.com>>>, Jamie.Obrien@steptoe-
`johnson.com<mailto:Jamie.Obrien@steptoe-johnson.com> <Jamie.Obrien@steptoe-
`johnson.com<mailto:Jamie.Obrien@steptoe-johnson.com<mailto:Jamie.Obrien@steptoe-
`johnson.com%3cmailto:Jamie.Obrien@steptoe-johnson.com>>>, Gordon.Copland@steptoe-
`johnson.com<mailto:Gordon.Copland@steptoe-johnson.com> <Gordon.Copland@steptoe-
`johnson.com<mailto:Gordon.Copland@steptoe-johnson.com<mailto:Gordon.Copland@steptoe-
`johnson.com%3cmailto:Gordon.Copland@steptoe-johnson.com>>>, DG-Aflibercept <DG-
`Aflibercept@NETORG8512690.onmicrosoft.com<mailto:DG-
`Aflibercept@NETORG8512690.onmicrosoft.com<mailto:DG-
`Aflibercept@NETORG8512690.onmicrosoft.com%3cmailto:DG-
`Aflibercept@NETORG8512690.onmicrosoft.com>>>, WFG-aflibercept@willkie.com<mailto:WFG-
`aflibercept@willkie.com> <WFG-aflibercept@willkie.com<mailto:WFG-
`aflibercept@willkie.com<mailto:WFG-aflibercept@willkie.com%3cmailto:WFG-
`aflibercept@willkie.com>>>, mhissam@hfdrlaw.com<mailto:mhissam@hfdrlaw.com>
`<mhissam@hfdrlaw.com<mailto:mhissam@hfdrlaw.com<mailto:mhissam@hfdrlaw.com%3cmailto:
`mhissam@hfdrlaw.com>>>, Carl Shaffer
`<cshaffer@hfdrlaw.com<mailto:cshaffer@hfdrlaw.com<mailto:cshaffer@hfdrlaw.com%3cmailto:csh
`affer@hfdrlaw.com>>>, Andrew Robey
`<arobey@hfdrlaw.com<mailto:arobey@hfdrlaw.com<mailto:arobey@hfdrlaw.com%3cmailto:arobe
`y@hfdrlaw.com>>>, Max Gottlieb
`<mgottlieb@hfdrlaw.com<mailto:mgottlieb@hfdrlaw.com<mailto:mgottlieb@hfdrlaw.com%3cmailt
`o:mgottlieb@hfdrlaw.com>>>, QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com<mailto:qe-samsungbioepis@quinnemanuel.com<mailto:qe-
`samsungbioepis@quinnemanuel.com%3cmailto:qe-samsungbioepis@quinnemanuel.com>>>,
`skl@schraderlaw.com<mailto:skl@schraderlaw.com>
`<skl@schraderlaw.com<mailto:skl@schraderlaw.com<mailto:skl@schraderlaw.com%3cmailto:skl@s
`chraderlaw.com>>>, clt@simmermanlaw.com<mailto:clt@simmermanlaw.com>
`<clt@simmermanlaw.com<mailto:clt@simmermanlaw.com<mailto:clt@simmermanlaw.com%3cmai
`lto:clt@simmermanlaw.com>>>, fes@simmermanlaw.com<mailto:fes@simmermanlaw.com>
`<fes@simmermanlaw.com<mailto:fes@simmermanlaw.com<mailto:fes@simmermanlaw.com%3cm
`ailto:fes@simmermanlaw.com>>>, trey@simmermanlaw.com<mailto:trey@simmermanlaw.com>
`<trey@simmermanlaw.com<mailto:trey@simmermanlaw.com<mailto:trey@simmermanlaw.com%3
`cmailto:trey@simmermanlaw.com>>>, SERVICE - Formycon Team <SERVICE-
`Formycon_Team@fr.com<mailto:SERVICE-Formycon_Team@fr.com<mailto:SERVICE-
`Formycon_Team@fr.com%3cmailto:SERVICE-Formycon_Team@fr.com>>>, MGB-Amgen-ABP938
`<MGB-Amgen-ABP938@marshallip.com<mailto:MGB-Amgen-
`ABP938@marshallip.com<mailto:MGB-Amgen-ABP938@marshallip.com%3cmailto:MGB-Amgen-
`ABP938@marshallip.com>>>, ABP938
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 9 of 13 PageID #: 2700
`
`<ABP938@rothwellfigg.com<mailto:ABP938@rothwellfigg.com<mailto:ABP938@rothwellfigg.com%
`3cmailto:ABP938@rothwellfigg.com>>>,
`REGENERONPATENT@lists.kellogghansen.com<mailto:REGENERONPATENT@lists.kellogghansen.co
`m>
`<REGENERONPATENT@lists.kellogghansen.com<mailto:REGENERONPATENT@lists.kellogghansen.co
`m<mailto:REGENERONPATENT@lists.kellogghansen.com%3cmailto:REGENERONPATENT@lists.kellog
`ghansen.com>>>, drpogue@cdkrlaw.com<mailto:drpogue@cdkrlaw.com>
`<drpogue@cdkrlaw.com<mailto:drpogue@cdkrlaw.com<mailto:drpogue@cdkrlaw.com%3cmailto:d
`rpogue@cdkrlaw.com>>>, sruby@cdkrlaw.com<mailto:sruby@cdkrlaw.com>
`<sruby@cdkrlaw.com<mailto:sruby@cdkrlaw.com<mailto:sruby@cdkrlaw.com%3cmailto:sruby@cd
`krlaw.com>>>, Ashley Hardesty Odell
`<ahardestyodell@bowlesrice.com<mailto:ahardestyodell@bowlesrice.com<mailto:ahardestyodell@
`bowlesrice.com%3cmailto:ahardestyodell@bowlesrice.com>>>, Kaitlyn McKitrick
`<kmckitrick@bowlesrice.com<mailto:kmckitrick@bowlesrice.com<mailto:kmckitrick@bowlesrice.co
`m%3cmailto:kmckitrick@bowlesrice.com>>>,
`Eylea.Biosimilars@weil.com<mailto:Eylea.Biosimilars@weil.com>
`<Eylea.Biosimilars@weil.com<mailto:Eylea.Biosimilars@weil.com<mailto:Eylea.Biosimilars@weil.co
`m%3cmailto:Eylea.Biosimilars@weil.com>>>, Eylea
`<Eylea@wc.com<mailto:Eylea@wc.com<mailto:Eylea@wc.com%3cmailto:Eylea@wc.com>>>
`
`Subject: RE: In re aflibercept - May 10 submission m/c
`
`
`
`Counsel,
`
`Celltrion, Formycon, and SB have served on Regeneron the categories of redacted documents to
`which we agreed in our May 30 email. We do not think Regeneron’s proposed protective order
`amendments are appropriate or necessary and do not agree to them, but are available to meet and
`confer on Friday if needed.
`
`Regards,
`
`
`
`Aviv Zalcenstein
`
`he/him/his
`
`
`
`[signature_211184720]
`
`Gemini Law LLP
`
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 10 of 13 PageID #: 2701
`
`40 W 24th Street Suite 6N
`
`New York, NY 10010
`
` o
`
` +1 917 226 7720
`
`
`azalcenstein@geminilaw.com<mailto:azalcenstein@geminilaw.com<mailto:azalcenstein@geminilaw
`.com%3cmailto:azalcenstein@geminilaw.com>> | geminilaw.com<http://www.geminilaw.com>
`
`
`
`*******************************************************************
`
`This message was sent from Gemini Law LLP and is intended only for the designated recipient(s). It
`may contain confidential or proprietary information and may be subject to the attorney-client
`privilege or other confidentiality protections. If you are not a designated recipient, you may not
`review, copy or distribute this message. If you receive this in error, please notify the sender by reply
`e-mail and delete this message. Thank you.
`
`*******************************************************************
`
`
`
`
`
`
`
`
`
`From: Brett A. Postal <bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>>
`
`Sent: Wednesday, June 5, 2024 2:39 PM
`
`To: Kayali, Kathryn <KKayali@wc.com<mailto:KKayali@wc.com>>; Robert Oakes
`<RMO@FR.com<mailto:RMO@FR.com>>; Laura Fairneny
`<laurafairneny@quinnemanuel.com<mailto:laurafairneny@quinnemanuel.com>>; Neil B.
`McLaughlin <NMcLaughlin@rmmslegal.com<mailto:NMcLaughlin@rmmslegal.com>>; Terri
`Mascherin <tmascherin@jenner.com<mailto:tmascherin@jenner.com>>
`
`Cc: Patel, Priyata <Priyata.Patel@weil.com<mailto:Priyata.Patel@weil.com>>; Mike Cottler
`<mcottler@geminilaw.com<mailto:mcottler@geminilaw.com>>; Shaun Van Horn
`<vanhorn@fr.com<mailto:vanhorn@fr.com>>; John R. Labbe
`<jlabbe@marshallip.com<mailto:jlabbe@marshallip.com>>; Argall, Arthur
`<aargall@wc.com<mailto:aargall@wc.com>>; M710 Team
`<M710Team@rmmslegal.com<mailto:M710Team@rmmslegal.com>>; Jamie.Obrien@steptoe-
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 11 of 13 PageID #: 2702
`
`johnson.com<mailto:Jamie.Obrien@steptoe-johnson.com>; Gordon.Copland@steptoe-
`johnson.com<mailto:Gordon.Copland@steptoe-johnson.com>; DG-Aflibercept <DG-
`Aflibercept@NETORG8512690.onmicrosoft.com<mailto:DG-
`Aflibercept@NETORG8512690.onmicrosoft.com>>; WFG-aflibercept@willkie.com<mailto:WFG-
`aflibercept@willkie.com>; mhissam@hfdrlaw.com<mailto:mhissam@hfdrlaw.com>; Carl Shaffer
`<cshaffer@hfdrlaw.com<mailto:cshaffer@hfdrlaw.com>>; Andrew Robey
`<arobey@hfdrlaw.com<mailto:arobey@hfdrlaw.com>>; Max Gottlieb
`<mgottlieb@hfdrlaw.com<mailto:mgottlieb@hfdrlaw.com>>; QE - Samsung Bioepis <qe-
`samsungbioepis@quinnemanuel.com<mailto:qe-samsungbioepis@quinnemanuel.com>>;
`skl@schraderlaw.com<mailto:skl@schraderlaw.com>;
`clt@simmermanlaw.com<mailto:clt@simmermanlaw.com>;
`fes@simmermanlaw.com<mailto:fes@simmermanlaw.com>;
`trey@simmermanlaw.com<mailto:trey@simmermanlaw.com>; SERVICE - Formycon Team
`<SERVICE-Formycon_Team@fr.com<mailto:SERVICE-Formycon_Team@fr.com>>; MGB-Amgen-
`ABP938 <MGB-Amgen-ABP938@marshallip.com<mailto:MGB-Amgen-ABP938@marshallip.com>>;
`ABP938 <ABP938@rothwellfigg.com<mailto:ABP938@rothwellfigg.com>>;
`REGENERONPATENT@lists.kellogghansen.com<mailto:REGENERONPATENT@lists.kellogghansen.co
`m>; drpogue@cdkrlaw.com<mailto:drpogue@cdkrlaw.com>;
`sruby@cdkrlaw.com<mailto:sruby@cdkrlaw.com>; Ashley Hardesty Odell
`<ahardestyodell@bowlesrice.com<mailto:ahardestyodell@bowlesrice.com>>; Kaitlyn McKitrick
`<kmckitrick@bowlesrice.com<mailto:kmckitrick@bowlesrice.com>>;
`Eylea.Biosimilars@weil.com<mailto:Eylea.Biosimilars@weil.com>; Eylea
`<Eylea@wc.com<mailto:Eylea@wc.com>>
`
`Subject: RE: In re aflibercept - May 10 submission m/c
`
`
`
`Dear Kat:
`
`
`
`As you are aware, last week defendants Formycon, SB, Celltrion, and Amgen reached agreement
`that redacted versions of specified PI-related documents from the respective proceedings in this
`MDL can be produced to Amgen. These include the briefs, declarations, and depositions transcripts
`on issues that are relevant to Regeneron’s forthcoming PI proceedings against Amgen. Each of
`Formycon, SB, and Celltrion consented to those documents being produced to Amgen today (L.
`Fairneny email to B. Postal of May 29, 2024). To be clear, it is now only Regeneron who has any
`objection to the production of these documents to Amgen.
`
`
`
`For months, Regeneron has agreed to produce these documents after receiving consent and
`redactions from the other defendants, or confirmation that the documents do not contain
`confidential information of other defendants. In your email of April 26, 2024, you specifically stated
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 12 of 13 PageID #: 2703
`
`that you would “promptly” produce these documents once the defendants’ confidentiality issues
`were resolved. (K. Kayali email to B. Postal of April 26, 2024.) Those issues were resolved a week ago,
`on May 29, through agreement and cooperation among the defendants listed above. We expect that
`Regeneron has already identified the referenced IQVIA data in the other litigation documents and
`can easily make any necessary redactions.
`
`
`
`While Amgen does not object to defendants providing their redacted documents directly to
`Regeneron, Regeneron must immediately produce those documents to Amgen tomorrow, June 6,
`2024. Thus, to address Regeneron’s purported objection, the production previously agreed-to
`among the defendants will move forward as planned, with the exception that such production will
`be directed to Regeneron’s counsel who will effectuate the production to Amgen, with any further
`redactions, by tomorrow.
`
`
`
`If Regeneron does not confirm by the end of today that it will produce to Amgen any and all
`redacted PI documents it receives from these other defendants by June 6, Amgen will be forced to
`move the Court for specific relief. We are hopeful that Regeneron will keep its promise to promptly
`produce these documents now that the other defendants have consented and provided redactions.
`However, if Regeneron does not confirm as much by the end of today, Amgen will need to ask the
`Court for expedited resolution, given the time sensitivity of these PI proceedings and Regeneron’s
`delay.
`
`
`
`With respect to Regeneron’s objection raised last night (which objection appears to be limited to the
`need to redact IQVIA data from certain documents), Amgen formally requested these materials from
`Regeneron in March. Since then, Regeneron has had multiple opportunities to raise these concerns.
`Instead, Regeneron waited until the night before Amgen expected receipt of the documents. Until
`last night, you stated that Regeneron’s position was that it would agree to produce these documents
`after receiving consent and redactions from the other defendants, or confirmation that the
`documents do not contain confidential information of the other defendants. That consent was given
`last week, and the defendants above have cooperatively agreed to produce redacted versions by
`today. As shown below, Regeneron has been on full notice of this agreement, and could have
`objected at any time:
`
`
`
`
`
` * During the parties’ meet and confer on May 28, 2024, Regeneron did not raise any objections
`with other Defendants’ production of litigation documents to Amgen.
`
`
`

`

`Case 1:24-cv-00053-TSK Document 17-6 Filed 06/12/24 Page 13 of 13 PageID #: 2704
`
`
`
`
`
`
`
` * On May 29 and 30, 2024, Regeneron was on the correspondence reflecting Formycon, SB, and
`Celltrion’s agreement with Amgen regarding the production of litigation documents by June 5, 2024.
`Regeneron did not raise any objections during those negotiations.
`
`
`
`
`
` * On May 31, 2024, I asked for confirmation that Regeneron would not object to the production of
`these litigation documents. Regeneron did not respond.
`
`
`
`
`
` * On June 3, 2024, I sent an email indicating that we had not yet heard from Regeneron, and thus,
`we understood that Regeneron did not have any objections. Regeneron did not respond until
`10:13pm on June 4, the eve of the date in which the litigation documents are to be produced.
`
`
`
`While Amgen is open to discussing ways to facilitate future efforts to provide parties in the MDL with
`appropriate and reciprocal access to information in these cases, such efforts (including your 10pm
`proposal of last night to modify all the protective orders) are independent of the agreement that the
`defendants reached, and Regeneron’s obligation to promptly produce these documents to Amgen.
`
`
`
`We look forward to your confirmation, no later than end of today, that Regeneron will produce
`these documents to Amgen by June 6. The parties have met and conferred numerous times on these
`issues.
`
`
`
`Regards,
`
`Brett
`
`
`
`